Marex Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Marex Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,232	Closed	-$195K	–	256
2022 Q4	$195K	Buy	+12,232	New	+$191K	0.03%	234

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marex Group's ACAD Position: Q1 2023 in Review

Marex Group sold out of Acadia Pharmaceuticals (ACAD) in Q1 2023, closing a stake of 12,232 shares — an estimated $195K sold.

Marex Group first reported a position in ACAD in Q4 2022 and held it in 1 quarter. The position peaked at $195K in Q4 2022. 233 funds tracked by Wall St. Rank hold ACAD as of Q1 2023.

Marex Group reported no remaining Acadia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Marex Group sold 12,232 Acadia Pharmaceuticals shares in Q1 2023, an estimated $195K.
Marex Group first reported a position in Acadia Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Marex Group's Acadia Pharmaceuticals position peaked at $195K in Q4 2022.
233 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2023.

Based on Marex Group's 13F filing for Q1 2023, filed 2 Apr 2026.